Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis’ Zelnorm Has 25% Adoption Rate Among Specialists After 2 Months

Executive Summary

The uptake of Novartis' irritable bowel syndrome therapy Zelnorm will accelerate after physicians obtain more "feedback" from early users, U.S. Commercial Operations General Manager Kurt Graves said Oct. 17 during a Novartis R&D briefing in New York City
Advertisement

Related Content

Novartis Zelnorm DTC Ads To Start In Fall; Resources Shifted From Field Force
Novartis Zelnorm DTC Ads To Start In Fall; Resources Shifted From Field Force
FDA Objects To Novartis IBS Ads; Claims Are Zelnorm-Specific, Agency Says
FDA Objects To Novartis IBS Ads; Claims Are Zelnorm-Specific, Agency Says
Novartis Zelnorm uptake
Novartis Zelnorm uptake
GSK Lotronex Plan Follows Accutane Model; Relaunch “Months” Away
GSK Lotronex Plan Follows Accutane Model; Relaunch “Months” Away
Novartis Zelmac Trade Name Could Be Changed Following FDA Discussions
Advertisement
UsernamePublicRestriction

Register

PS040659

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel